Urinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary syndrome: A pilot study considering neglected steroid metabolites by Dhayat, Nasser et al.
1 
Urinary steroid profiling in women hints at a diagnostic signature of the polycystic ovary 1 
syndrome: A pilot study considering neglected steroid metabolites 2 
3 
Nasser A. Dhayat1, Nesa Marti2, Zahraa Kollmann3, Amineh Troendle4, Lia Bally5, Geneviève 4 
Escher1, Michael Grössl1, Michael Müller3, Bruno Vogt1,7, Martin H. Birkhäuser3, Murielle Bochud6,7, 5 
Christa E. Flück2 6 
7 
1Department of Nephrology and Hypertension and Department of BioMedical Research, Inselspital, 8 
University Hospital, University of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland; 9 
Email: Nasser.dhayat@insel.ch; Genevieve.escher@insel.ch; Michael.groessl@insel.ch; 10 
Bruno.vogt@insel.ch;  11 
2Pediatric Endocrinology and Diabetology, Department of Pediatrics and Department of BioMedical 12 
Research, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 15, 3010 Bern, 13 
Switzerland; 14 
Email: nesa.m.marti@gmail.com; christa.flueck@dbmr.unibe.ch;  15 
3Department of Obstetrics and Gynecology, Inselspital, Bern University Hospital, University of Bern, 16 
3010 Bern, Effingerstrasse 102, 3010 Bern, Switzerland;  17 
Email: zahraa.kollmann@googlemail.com; Michael.mueller@insel.ch; 18 
martin.birkhaeuser@balcab.ch;  19 
4Lindenhofspital, Bremgartenstrasse 117, 3001 Bern, Switzerland; 20 
Email: amineh.troendle@lindenhofgruppe.ch; 21 
5Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism, Inselspital, Bern 22 
University Hospital, University of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland; 23 
Email: lia.bally@insel.ch;  24 
6Institute of Social and Preventive Medicine, University Hospital of Lausanne, Route de la Corniche 25 
10, 1010 Lausanne, Switzerland; 26 
Manuscript
2 
Email: murielle.bochud@chuv.ch;  27 
7Swiss Kidney Project on Genes in Hypertension (SKIPOGH) Study Group 28 
29 
Collaborators of the SKIPOGH Study Group: 30 
Daniel Ackermann1, Michel Burnier2, Georg Ehret3, Idris Guessous4, Pierre-Yves Martin5, Fred 31 
Paccaud6, Antoinette Pechère-Bertschi7, Belen Ponte5, Menno Pruijm2 32 
1Department of Nephrology and Hypertension and Department of BioMedical Research, Inselspital, 33 
University Hospital, University of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland; 2Nephrology 34 
Service, University Hospital of Lausanne, Rue du Bugnon 17, 1011 Lausanne, Switzerland; 35 
3Cardiology Service, Department of Specialties of Internal Medicine, University Hospital of Geneva, 36 
avenue de la Roseraie 64, 1211 Genève 4, Switzerland; 4Department of Community Medicine, 37 
Primary Care and Emergency Medicine, University Hospital of Geneva, Rue Gabrielle-Perret-Gentil 38 
4, 1205 Genève, Switzerland; 5Nephrology Service, Department of Specialties of Internal Medicine, 39 
University Hospital of Geneva, rue Gabrielle-Perret-Gentil 4, 1211 Genève 14, Switzerland; 40 
6Institute of Social and Preventive Medicine, University Hospital of Lausanne, Route de la Corniche 41 
10, 1010 Lausanne, Switzerland; 7Endocrinology Service, Department of Internal Medicine 42 
Specialties, University Hospital of Geneva, Rue Gabrielle Perret-Gentil 4, 1205 Genève, 43 
Switzerland. 44 
45 
Key terms: polycystic ovary syndrome, PCOS; urinary steroid metabolome; androgen biosynthesis; 46 
classic pathway; alternative androgen pathways 47 
48 
Corresponding author and person to whom reprint requests should be addressed: 49 
Christa Flück, M.D., University Children’s Hospital Bern, Freiburgstrasse 15 / C845, 3010 Bern, 50 
Switzerland, Phone: +41 31 632 04 99. Email: christa.flueck@dbmr.unibe.ch 51 
3 
Abstract  52 
Background: Although the polycystic ovary syndrome (PCOS) is the most common endocrine 53 
disorder in women with vast metabolic consequences, its etiology remains unknown and its 54 
diagnosis is still made by exclusion. This study aimed at characterizing a large number of urinary 55 
steroid hormone metabolites and enzyme activities in women with and without PCOS in order to 56 
test their value for diagnosing PCOS. 57 
Methods: Comparative steroid profiling of 24h urine collections using an established in-house gas-58 
chromatography mass spectrometry method. Data were collected mostly prospectively. Patients 59 
were recruited in university hospitals in Switzerland. Participants were 41 women diagnosed with 60 
PCOS according to the current criteria of the Androgen Excess and PCOS Society Task Force and 61 
66 healthy controls. Steroid profiles of women with PCOS were compared to healthy controls for 62 
absolute metabolite excretion and for substrate to product conversion ratios. The AUC for over 1.5 63 
million combinations of metabolites was calculated in order to maximize the diagnostic accuracy in 64 
patients with PCOS. Sensitivity, specificity, PPV, and NPV were indicated for the best combinations 65 
containing 2, 3 or 4 steroid metabolites. 66 
Results: The best single discriminating steroid was androstanediol. The best combination to 67 
diagnose PCOS contained four of the forty measured metabolites, namely androstanediol, estriol, 68 
cortisol and 20βDHcortisone with AUC 0.961 (95% CI 0.926 to 0.995), sensitivity 90.2% (95% CI 69 
76.9 to 97.3), specificity 90.8% (95% CI 81.0 to 96.5), PPV 86.0% (95% CI 72.1 to 94.7), and NPV 70 
93.7% (95% CI 84.5 to 98.2). 71 
Conclusion: PCOS may be diagnosed by steroid profiling, if neglected metabolites are included in 72 
the analysis and non-conventional data analysis applied. Diagnosis by exclusion may no longer be 73 
warranted. Whether these findings also apply to spot urine and serum, remains to be tested as a 74 
next step towards routine clinical applicability. 75 
4 
Introduction 76 
Polycystic ovary syndrome (PCOS) affects about 10% of women and may have major reproductive 77 
and metabolic consequences. PCOS is diagnosed by exclusion mainly because of lack of 78 
knowledge of its complex pathomechanism. Current criteria for diagnosing PCOS by the Androgen 79 
Excess and PCOS Society  comprise one, androgen excess by clinical and/or biochemical means, 80 
and two, ovulatory dysfunction and/or polycystic ovaries by morphology (1, 2). PCOS patients are 81 
often insulin resistant and obese, have often a positive family history, encountered often premature 82 
adrenarche, or were born small for gestational age. Overall, hyperandrogenism seems to play an 83 
essential role in PCOS manifesting clinically as acne, hirsutism, and menstrual disturbances. 84 
Biochemically, elevated serum androgens and increased AMH and LH levels may be found, but to 85 
date there is no reliable diagnostic laboratory test for diagnosing PCOS. Unspecific disturbances of 86 
the steroid profile are often observed, but no diagnostic pattern has been identified so far. 87 
Androgens are produced primarily in the gonads and the adrenal cortex. In women about 25% of 88 
circulating androgens originate from the adrenals, 25% from the ovaries, and 50% from peripheral 89 
conversion of precursor steroids (3, 4). Normally, plasma testosterone concentrations in a 30 year 90 
old female are about 10-fold lower compared to an age-matched male, but may be markedly 91 
elevated with PCOS.  92 
The classic androgen biosynthesis pathway in the adrenal cortex zona reticularis (ZR) and the 93 
human ovary is long known and follows the Δ5-pathway from cholesterol to 17-94 
hydroxypregnenolone to dehydroepiandrosterone (DHEA), the first androgen precursor (5). In the 95 
ZR, the theca cell of the ovary, and in peripheral tissues, DHEA is converted to androstenedione, 96 
which is thereafter mainly converted to estrogens and only in little quantities to testosterone (T), 97 
either in the ovary or in peripheral tissues. Finally, some T may be further converted to 98 
dihydrotestosterone (DHT), the most potent androgen. Recently, an alternative pathway for 99 
androgen biosynthesis has been described first in the tammar wallaby (6), then in humans (7). In 100 
this alternative, backdoor pathway 17-hydroxyprogesterone or 17-hydroxypregnenolone is driven 101 
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away from the classic pathway by 5α-3α reducing reactions yielding 17-hydroxy-allopregnanolone, 102 
which is then converted to androsterone and androstanediol or androstanedione before yielding 103 
DHT. A role for this alternative pathway has been established for the human testis (8) and the 104 
adrenal cortex (9, 10); and it has been suggested for the human ovary from immunohistochemical 105 
studies (11), and from steroid profiling in PCOS (12). However, whether this pathway plays a role 106 
for excess androgen production awaits further confirmation. It has been reported that in PCOS 107 
increased 5α reductase activity converts androstenedione to androstanedione, which is then 108 
converted to DHT (13). In line with that, we found increased 5α reductase expression in PCOS 109 
ovaries (11). Furthermore, newer studies show that the adrenal ZR (and maybe the theca cells) 110 
produce 11-OH-androstenedione, which can be converted to potent androgens such as 11-111 
ketotestosterone (14). Accordingly, elevated serum concentrations of 11-oxygenated androgens 112 
were measured in women with PCOS (15). But albeit all these novel findings, there is still no 113 
diagnostic laboratory test for PCOS. 114 
Therefore in this study, we performed comprehensive steroid metabolic profiling of urine specimens 115 
obtained from PCOS women and compared it to healthy, matched controls in order to find PCOS 116 
characteristic changes for diagnostic use. We assessed 40 steroid metabolites and analyzed them 117 
for significant differences between groups looking at the level of single metabolites and at ratios 118 
characterizing enzyme activities. We also searched for androgens produced by alternative 119 
pathways. In addition, unbiased data analysis was performed by calculating systematically 120 
combinations of steroid metabolites aiming at finding a diagnostic classifier that would be able to 121 
discriminate PCOS from controls.  122 
 123 
Materials and Methods 124 
Study design and participants 125 
The study was approved by the ethics commission of the Kanton Bern, Switzerland (study 126 
ID004/07). Participants provided informed consent. The study was partially retrospective for the 127 
6 
PCOS group and fully prospective for the healthy control group. Study inclusion was possible for 128 
patients with a PCOS diagnosis according to the Androgen Excess and PCOS Society (1). 129 
Females were postmenarchal (13 to 46 years), without hormonal treatments and without other 130 
disease conditions. A 24h-urine sample collection was mandatory. The matched control group was 131 
recruited in parallel with the Swiss Kidney Project on Genes in Hypertension (SKIPOGH) study (16, 132 
17), means healthy controls participated in both studies and did not have PCOS. Of the 1128 133 
healthy SKIPOGH participants, 591 are women, 264 were ≤ 46 years at the time of urine sampling. 134 
Out of these 264 women, 187 were excluded for medication intake (e.g. anticonception), 7 for 135 
irregular periods, 3 for missing urine steroid measurements, and one for diagnosis of PCOS; 136 
leaving 66 eligible control participants. 137 
138 
Sample collection and biochemical measurements 139 
Study participants were instructed to collect 24-hour urine. Samples were stored at ≥-20°C before 140 
assessing the steroid profile with an in-house method of gas chromatography, mass spectrometry 141 
(GC-MS) (18). In brief, the method comprises a pre-extraction on a Sep-Pak C18 column, an 142 
enzymatic hydrolysis following extraction on a Sep-Pak C18 cartridge, derivatization and 143 
purification on a Lipidex 5000 column. A gas chromatograph 7890A from Agilent Technologies (La 144 
Jolla, California, USA) coupled to a mass selective detector Hewlett-Packard 5975C providing 145 
selected ion monitoring (SIM) was used. Further details about the steroid compounds and the GC-146 
MS method are reported in (18). Fasting blood samples were analysed by standard laboratory 147 
methods. The homeostasis model assessment insulin resistance (HOMA-IR) and beta-cell function 148 
(HOMA-β) were used to assess insulin resistance and beta-cell function (19). 149 
150 
Statistical analyses 151 
All statistical analyses were performed using R (version 3.2.5; R Foundation for Statistical 152 
Computing, Vienna). All tests were two-sided and a p value <0.05 was considered statistically 153 
7 
significant unless otherwise stated. The shape of the distribution of quantitative urinary steroid 154 
hormone metabolites and of steroid hormone ratios was visualized and transformations were 155 
applied to dependent variables in uni- and multivariable linear regression analyses. Regression 156 
models were graphically validated and revealed no obvious deviations from homoscedasticity or 157 
normality. The accuracy of different classifier to discriminate women into PCOS and healthy was 158 
assessed by the area under the curve (AUC) and its 95% CI of a receiver operating characteristic 159 
(ROC) analysis using the statistical R packages “pROC”, “ROCR”, and “Epi”. Performance of all 40 160 
steroid metabolites and their ratios including sums and products of log, square root and square 161 
were analysed to find the best classifiers. Combinations of 2 or 3 steroid metabolites were 162 
analysed, thereby investigating far more than one million possible combinations. To increase the 163 
AUC under the ROC curve, the best discriminating combinations of 3 classifiers were further 164 
optimized by stepwise adding and omitting additional metabolites. Sensitivity-specificity versus 165 
classifier plot were created for the best classifiers to indicate the threshold where sensitivity and 166 
specificity are simultaneously maximized using the R package “OptimalCutpoints”, and the 167 
corresponding contingency tables with test characteristics were produced. Multivariable regression 168 
models containing four classifiers were described and visualized using the R package “visreg”. 169 
170 
Results 171 
Baseline characteristics of the study population 172 
Baseline characteristics are listed in S1 Table. The PCOS group was younger compared to controls 173 
with a median age of 27 versus 34 years (range 13-46 versus 18-46 years, p<0.001). BMI was not 174 
significantly different. Resting systolic blood pressure was higher in the PCOS group with a median 175 
of 115 versus 109 mmHg (range 100-140 versus 86-148 mmHg, p<0.01). No difference was 176 
observed for resting diastolic blood pressure. Fasting plasma glucose was similar in both groups, 177 
but serum insulin was higher in PCOS subjects with a median of 16.6 versus 3.2 mU/l (range 5.2-178 
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26.7 versus 1-19 mmHg, p<0.001). Accordingly, both HOMA-IR and HOMA-β were higher in the 179 
PCOS group compared to controls indicating insulin resistance in PCOS. 180 
181 
24-hour urine steroid metabolite excretion182 
Comparison of 24-hour urine steroid metabolite excretion between PCOS and controls by Mann-183 
Whitney U test, and by uni- and multivariable linear regression analyses is summarized in Table 1 184 
(and S2 Table). The largest increase in median steroid metabolite excretion was found in the 185 
PCOS group for dehydroepiandrosterone (4.9-fold, p<0.001), androstenediol (3.0-fold, p<0.001), 186 
pregnenetriol (2.8-fold, p<0.001), 16α-OH-dehydroepiandrosterone (2.3-fold, p<0.001) and 187 
androstanediol (2.3-fold, p<0.001). Higher excretion was found in controls for pregnanediol (1.6-188 
fold, p=0.0019) and estriol (1.4-fold, p=0.027). In multivariable analyses a higher excretion was 189 
found in PCOS for 14 steroid compounds, including 9 androgens and 4 glucocorticoids. Lower 190 
excretion of pregnanediol and estriol in PCOS persisted even after adjustement for age and BMI 191 
(Table 1). Results of the multivariable analyses are depicted in Figure 1. 192 
193 
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Table 1. Steroid hormone excretion in women with the polycystic ovary syndrome (PCOS) compared to healthy control women. The available 
number of participants (N) and the distribution described by median and 25th-75th quantile for the PCOS and control group are indicated for each 
steroid. Between-group differences are determined by Mann–Whitney U test (MWU) and the corresponding P values are indicated. Univariable and 
multivariable models were calculated by linear regression. Univariable models contain the PCOS-/control-group as predictor variable (with controls as 
reference group). Multivariable models contain in addition the covariables age and BMI. The dependent variables in the models were transformed as 
indicated. The β coefficients and the corresponding 95% confidence intervals (CI) are reported in the transformed scale and the corresponding P 
values are indicated. Note, only steroid hormones with a significant difference in the amount excreted in 24 hours in women with PCOS compared to 
healthy controls are shown here. Results for all 40 steroid hormones measured are displayed in Supplemental Table II. 
Steroid hormone, nmol/24h 
Dependent variable in Models
Controls PCOS MWU Univariable Models Multivariable Models 
N Median 25th-75th N Median 25th-75th P β 95% CI P β 95% CI P 
Androg s and m tabolites 
dehydroepiandrosteronea 66 293 136-853 41 1435 390-3895 <0.001 1.27 0.712;1.83 <0.001 1.03 0.437;1.62 <0.001 
16α-OH-dehydroepiandrosteronea 66 676 314-1213 41 1577 701-3321 <0.001 0.740 0.289;1.19 0.0015 0.740 0.289;1.19 0.0015 
androstenediola 66 205 125-430 41 622 405-1314 <0.001 1.07 0.705;1.43 <0.001 0.858 0.483;1.23 <0.001 
testosteronea 63 34 21-58 33 52 34-84 0.013 0.449 0.106;0.793 0.011 0.427 0.05;0.804 0.027 
5α-DH-testosteronea 65 36 23-55 33 56 44-88 0.0057 0.477 0.148;0.805 0.0049 0.387 0.029;0.746 0.035 
androstanediola 65 108 65-142 41 250 185-350 <0.001 0.930 0.735;1.13 <0.001 0.886 0.68;1.09 <0.001 
androsteroneb 57 3983 2651-5433 41 8354 4909-11808 <0.001 24.9 15.7;34 <0.001 14.7 6.31;23 <0.001 
11β-OH-androsteroneb 66 1385 1049-2048 41 2210 1618-3263 <0.001 9.80 5.35;14.2 <0.001 8.73 4.2;13.3 <0.001 
etiocholanoloneb 61 4075 2823-5709 41 5893 4558-8210 <0.001 13.5 6.3;20.6 <0.001 9.65 2.13;17.2 0.012 
Estrogens 
estriola 66 29 16-49 41 21 8-34 0.027 -0.444 -0.809;-0.079 0.018 -0.491 -0.877;-0.105 0.013 
Glucocorticoids and metabolites 
6β-OH-cortisola 66 222 147-348 41 319 189-445 0.025 0.238 -0.012;0.489 0.062 0.256 -0.016;0.529 0.065 
18-OH-cortisolb 61 434 301-607 39 676 448-924 <0.001 5.75 3.1;8.39 <0.001 5.89 3.02;8.76 <0.001 
TH-cortisolb 59 2770 1926-3439 41 3613 2603-4404 0.0017 8.06 2.85;13.3 0.0028 7.91 2.72;13.1 0.0032 
11β-OH-etiocholanoloneb 66 872 410-1196 40 1037 255-1640 0.51 1.87 -2.92;6.67 0.44 5.75 0.837;10.7 0.022 
TH-cortisoneb 64 5551 3394-7209 41 8559 5651-13063 <0.001 23.8 14.8;32.9 <0.001 21.2 12;30.4 <0.001 
aDependent variable natural log transformed in regression models. 
bDependent variable square root transformed in regression models. 
194 
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Figure 1. Scheme of alterations in 24-hour urine steroid excretion and steroid enzyme 195 
activities in PCOS compared to controls adjusted for age and BMI in multivariable analyses. 196 
Abbreviations: DHEA: dehydroepiandrosterone. An “OH” in enzyme names indicates a 197 
hydroxylase. An “OH” in steroid names indicates a hydroxyl group. DH: dehydro; TH: tetrahydro; 198 
HSD: hydroxysteroid dehydrogenase; POR: P450 oxidoreductase; Cyt b5: Cytochrome b5; 5α-R: 199 
5α reductase; 5β-R: 5β reductase.  200 
201 
Steroid enzyme activities 202 
Steroid enzyme activities were assessed by metabolite ratios as published (20), and were 203 
compared between PCOS and controls by Mann–Whitney U test and by uni- and multivariable 204 
regression models (Table 2 and S3 Table). Steroid metabolite substrate to product conversion 205 
ratios representing 21-hydroxylase activity were lower in PCOS indicating an increased 21-206 
hydroxylase activity in PCOS compared to controls. This association persisted in multivariable 207 
regression analyses adjusted for age and BMI. 3β-hydroxysteroid dehydrogenase (3β-HSD) activity 208 
seemed lower in PCOS, but this association to PCOS disappeared after multivariable adjustment. 209 
By contrast, a higher enzyme activity was found in PCOS for the activities of 11β-hydroxylase, and 210 
the Δ4-pathway activity of 17α-hydroxylase and 17,20-lyase, as well as for the P450 211 
oxidoreductase activity. For the activity of 17β-hydroxysteroid dehydrogenase multivariable 212 
analyses indicated no difference. Similarly, no clear difference was found for the ratio yielding 213 
androgen synthesis through the backdoor pathway or for 5α reductase activity. A lower activity in 214 
PCOS was found for aromatase after adjusting for age and BMI. A higher 11β-hydroxysteroid 215 
dehydrogenase (11β-HSD) type 2 and a lower 11β-HSD type 1 activity was found for PCOS for 216 
some calculated ratios, whereas other ratios indicated no difference. The activities of 20α- and 20β-217 
hydroxysteroid dehydrogenases (20α/β-HSD) were both lower in PCOS, while 3α-hydroxysteroid 218 
dehydrogenase (3α-HSD) activity was higher in PCOS. These results are also depicted in Figure 1. 219 
220 
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Table 2. Steroid hormone enzyme activities represented by selected steroid hormone metabolite ratios in women with polycystic ovary syndrome compared to healthy women. The available 
number of participants (N) and median and 25th-75th quantile are indicated. Between-group differences are determined by Mann–Whitney U test (MWU). Univariable and multivariable models are 
calculated by linear regression with transformed steroid hormone metabolite as dependent variable. Univariable models contain the PCOS group as predictor variable (with controls as reference 
group). Multivariable models contain in addition the covariables age and BMI. The β coefficients and the corresponding 95% confidence intervals (CI) are reported on the transformed scale. Note 
that only significant different ratios are shown here, while the results for all calculated steroid hormones ratios are displayed in Supplemental Table III. 
Enzyme activities and 
corresponding ratios
Controls PCOS MWU Univariable Models Multivariable Models 
N Median 25th-75th N Median 25th-75th P β 95% CI P β 95% CI P 
21-Hydr xylase 
PTO/THEa 64 0.005 0.004-
0.008
41 0.003 0.003-
0.007
0.0045 -0.368 -0.656;-0.08 0.013 -0.378 -0.689;-0.068 0.017 
3β-hydroxysteroid dehydrogenase 
5PT/THEb 64 0.060 . 31-
0.097
41 0.087 . 46-
0.158
0.025 0.056 0.005;0.107 0.031 0.020 -0.032;0.072 0.45 
11β-hydroxylase 
THS/THEa 64 0.023 . 18-
0.031
41 0.015 .011-
0.019
<0.001 -0.426 -0.622;-0.23 <0.001 -0.352 -0.559;-0.145 0.0011 
CYP17 global (17α-hydroxylase and 17,20-lyase) 
PD/(AT+ET)a 51 0.147 . 73-
0.384
41 0.056 . 38-
0.069
<0.001 -1.17 -1.56;-0.777 <0.001 -0.943 -1.35;-0.535 <0.001 
17α-hydroxylase global 
THA+THB+5αTHB/THEb 64 0.221 .176-
0.279
41 0.157 .11-0.211 <0.001 -0.068 -0.1;-0.036 <0.001 -0.062 -0.097;-0.027 <0.001 
17α-hydroxylase Δ4-pathway 
PD/17HPa 62 4.77 2.88-7.84 41 2.42 1.43-4.1 <0.001 -0.635 -0.927;-0.343 <0.001 -0.540 -0.854;-0.227 <0.001 
17,20-lyase global 
(AT+ET)/THEb 52 1.60 1.1-2.17 41 1.48 0.999-2.68 0.77 0.032 -0.119;0.183 0.67 -0.045 -0.2;0.111 0.57 
17,20-lyase Δ5-pathway 
5PT/(DHEA+16OHDHEA)a 66 0.230 0.146-0.57 41 0.234 0.12-0.394 0.32 -0.084 -0.45;0.282 0.65 -0.164 -0.56;0.231 0.41 
17,20-lyase Δ4-pathway 
17HP/(AT+ET)a 52 0.030 0.02-0.066 41 0.023 0.013-
0.032
0.0038 -0.538 -0.864;-0.212 0.0015 -0.423 -0.772;-0.074 0.018 
CYP17 global Δ4- vs. Δ5-pathway 
11βOHAT/(DHEA+16OHDHEA+Δ5diol)a 66 1.14 0.554-1.95 41 0.464 .304-1.26 0.0017 -0.669 -1.04;-0.295 <0.001 -0.470 -0.863;-0.077 0.020 
17β-hydroxysteroid dehydrogenase 
(ET+AT)/(THE+THF+5αTHF)a 48 0.834 0.624-1.24 41 0.893 0.563-1.46 0.40 0.087 -0.156;0.33 0.48 -0.050 -0.296;0.196 0.69 
5α-reductase 
ET/ATa 53 1.09 0.899-1.36 41 0.798 0.561-1.15 0.0035 -0.282 -0.463;-0.101 0.0026 -0.114 -0.288;0.06 0.20 
Aromatase (CYP19A1) 
testosterone/17β-estradiola 63 2.8 1.64-7.56 33 8.21 3.63-15.7 0.0012 0.725 0.271;1.18 0.0020 0.565 0.087;1.04 0.021 
11β-hydrosteroid dehydrogenase type 2 
(F+E)/(THF+5αTHF+THE)c 58 0.812 0.757-
0.858
41 0.837 0.797-
0.882
0.099 0.053 -0.009;0.115 0.092 0.085 0.018;0.151 0.013 
11β-hydrosteroid dehydrogenase type 1 
THE/(THF+5αTHF)a 58 1.08 .946-1.41 41 1.47 1.19-1.82 <0.001 0.278 0.151;0.404 <0.001 0.272 0.133;0.41 <0.001 
20α-hydrosteroid dehydrogenase 
(THF+5αTHF+THE)/(αC+αCl)a 57 1.66 1.28-1.93 41 1.85 1.5-2.32 0.011 0.240 0.089;0.392 0.0022 0.362 0.21;0.515 <0.001 
20β-hydrosteroid dehydrogenase 
(THF+5αTHF+THE)/βC+βCla 59 2.56 1.97-3.26 41 3.04 2.54-4.19 0.0065 0.230 0.08;0.38 0.0030 0.332 0.177;0.486 <0.001 
20α-hydrosteroid dehydrogenase vs. 20β-hydrosteroid dehydrogenase 
(αC+αCl)/(βC+βCl)a 61 1.64 1.37-2.07 41 1.54 1.34-2.05 0.85 -0.004 -0.126;0.119 0.95 -0.033 -0.165;0.1 0.62 
3α-hydroxysteroid dehydrogenase 
12 
20αDHF/(THF+5αTHF)a 59 0.025 0.017-0.04 40 0.020 0.01-0.032 0.042 -0.365 -0.652;-0.077 0.014 -0.391 -0.701;-0.081 0.014 
Abbreviations used for steroid compounds: 17HP: 17-OH-pregnanolone, PT: Pregnanetriol, 5PT: Pregnenetriol, PTO: Pregnanetriolone, PD: Pregnanediol, DHEA: Dehydroepiandrosterone, 
16OHDHEA: 16α-OH-dehydroepiandrosterone, Δ5-diol: Androstenediol, 5α3αdiol: Androstanediol, AT: Androsterone, 11βOHAT: 11β-OH-androsterone, ET: Etiocholanolone, THA: 11-dehydro-
TH-corticosterone, THB: TH-corticosterone, 5αTHB: Allo-TH-corticosterone, THS: TH-11-deoxycortisol, F: Cortisol, 20αDHF: 20α-DH-cortisol, THF: TH-cortisol, αC: α-Cortol, βC: β-Cortol, 
11βOHET: 11β-OH-etiocholanolone, 5αTHF: Allo-TH-cortisol, E: Cortisone, THE: TH-cortisone, αCl: α-Cortolone, βCl: β-Cortolone. aDependent variable natural log transformed in the models. 
bDependent variable square root transformed in the models. cDependent variable quartic (x4) transformed in the models. 
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Predicting PCOS by steroid metabolome 222 
The diagnostic performance of urinary steroid metabolites in the prediction of PCOS was assessed. 223 
Considering each urinary steroid metabolite separately, the androgen androstanediol (5α3αdiol) 224 
was the best classifier with the highest AUC in the ROC analysis (0.919, 95% CI: 0.867-0.971; 225 
Figure 2A). Maximizing the sensitivity and specificity simultaneously in a sensitivity-specificity-plot 226 
(Figure 2B) yielded an optimal threshold for urinary androstanediol at  ≥152 nmol/24 hours for the 227 
prediction of PCOS with a sensitivity of 90.2 (95% CI: 76.9-97.3), a specificity of 81.5 (95% CI: 228 
70.0-90.1), a positive predictive value of 75.5 (95% CI: 61.9-92.3), and a negative predictive value 229 
of 93.0 (95% CI: 82.6-96.5) (Figure 2C). 230 
231 
Figure 2. Diagnostic performance of urinary steroid metabolites in the prediction of PCOS. 232 
ROC curves for different classifiers of urinary steroid metabolites are shown on the left side, the 233 
corresponding plots of sensitivity-specificity versus the classifier are shown in the middle, and 234 
corresponding contingency tables on the right hand side. Dashed lines around the ROC curves 235 
indicate the 95% CI of the sensitivity at the given specificity. The AUC and its 95% CI is indicated. 236 
The dashed vertical lines in the sensitivity-specificity versus classifier plots indicate the threshold 237 
where sensitivity and specificity are simultaneously maximized. The main diagnostic performance 238 
parameters corresponding to this threshold are indicated. A-C. Classifier androstanediol. D-F. 239 
Classifier: (androstanediol1.5×20β-DH-cortisone)/(20β-DH-cortisone+[cortisol× log(estriol)]) 240 
represents the best combination of 4 steroid metabolites. Abbreviations: 5α3αdiol: androstanediol, 241 
F: cortisol, 20βDHE: 20β-DH-cortisone, PPV: positive predictive value, NPV: negative predictive 242 
value, log: natural logarithm. 243 
244 
Performance of urine steroid metabolite ratios for predicting PCOS by systematic calculations was 245 
also assessed. The best ratio combining 2 steroid metabolites comprised androstanediol and 246 
estriol, and was 5α3αdiol/log(5α3αdiol×estriol) with an AUC of 0.935 (95% CI: 0.889-0.981) under 247 
14 
the ROC curve (S1 Figure, D-F). The best combination of 3 urinary steroids was 248 
(5α3αdiol×20βDHE)/(20βDHE+cortisol) with an AUC of 0.949 (95% CI: 0.910-0.989) under the 249 
ROC curve (S1 Figure, G-I). Finally, the best predictive combination of 4 urinary steroids was 250 
(androstanediol1.5×20βDHcortisone)/ [20βDHcortisone+(cortisol×log(estriol))] with an AUC of 0.961 251 
(95% CI: 0.926-0.995) under the ROC curve (Figure 2, D-F) yielding a positive predictive value of 252 
86.0% and a negative predictive value of 93.7 % for the diagnosis of PCOS at the threshold 253 
indicated. 254 
To explore if age and BMI influence these predictors, a multivariable analysis was performed. BMI 255 
showed a positive association with all predictors in both PCOS and healthy women (S4 Table and 256 
S2 Figure), indicating that body weight increases the tests’ sensitivity while decreasing specificity. 257 
For only two predictors age had a different effect on PCOS and healthy controls (S2 Figure C, D). 258 
While in PCOS no age-effect was observed, healthy controls showed decreasing ratios with 259 
increasing age suggesting that both tests’ sensitivity and specificity are improving with age. 260 
Finally for proof of principal, we tested the identified diagnostic classifiers on 12 urinary steroid 261 
profiles that were recently analyzed in our GC-MS laboratory: 10 urines were from suspected 262 
PCOS women and sent for excluding 21-hydroxylase deficiency, 2 samples originated from 263 
subjects with 21-hydroxylase deficiency. Results were compared to study controls and PCOS, and 264 
are shown in Figure 3. The 2 samples from subjects with genetically confirmed CYP21A2 mutations 265 
showed an increased ratio for 17-OH-prenalonone/TH-cortisone confirming CYP21A2 deficiency 266 
(Figure 3A). Among the other 10 samples, 9 samples classified for PCOS according to 267 
androstanediol levels (Figure 3B), while 6 of 10 samples qualified for PCOS according to the more 268 
complex best ratio calculation including four metabolites (Figure 3C). 269 
270 
Figure 3. Prospective evaluation of PCOS classifiers. Black points scattered within the boxplots 271 
represent study participants. The ten not-filled point symbols between the boxplots represent urine 272 
profiles from suspected PCOS women, which were sent to our lab for excluding hyperandrogenism 273 
15 
due to 21-hydroxylase deficiency, while the two black-filled point symbols represent urine profiles 274 
from women with genetically confirmed 21-hydroxylase deficiency. The dashed horizontal lines 275 
indicate the diagnostic thresholds of PCOS classifiers. A. 21-hydroxylase activity. A higher ratio of 276 
17-OH-pregnanolone/TH-cortisone indicates a lower 21-hydroxylase activity. B. Classifier277 
androstanediol. C. Classifier (androstanediol1.5×20β-DH-cortisone)/(20β-DH-cortisone+[cortisol× 278 
log(estriol)]). 279 
280 
Discussion 281 
Our pilot study suggests that it is possible to diagnose the (hyperandrogenic) PCOS from urine 282 
metabolomics, and that PCOS may no longer be a diagnosis by exclusion. Androgen excess is the 283 
most characteristic finding in women with PCOS (2). Nevertheless, no diagnostic test for PCOS 284 
based on androgens had been identified so far, although enormous efforts have been undertaken. 285 
Reasons for this shortcoming are manifold and include the following: PCOS is a complex disorder 286 
likely representing the phenotypical endpoint of multiple underlying disorders leading to androgen 287 
excess through several pathways (1, 2). Studies measuring androgens in PCOS lack 288 
standardization with respect to preanalytical as well as analytical items and are therefore not 289 
comparable. Although in most clinical studies androgens are measured in blood, timing of sampling 290 
and specific androgens measured differ. In addition, methods of measurements vary and most 291 
immunoassays perform poorly with respect to specificity, availability of normative data as well as 292 
standardization across laboratories. Therefore, the scientific community has recommended 293 
chromatographic, mass spectrometric techniques for steroid and androgen measurements 294 
specifically.  295 
296 
We measured 40 steroid metabolites in 24h-urine specimens from PCOS women and compared 297 
them to controls using an established in-house GC-MS method (18). In the past 5-10 years several 298 
studies have measured androgens in serum of PCOS women using either GC-MS or LC-MSMS 299 
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techniques (12, 15, 21, 22), but we found only one recent study assessing the steroids from urine 300 
samples (23). Not surprisingly, all studies (ours included) found elevated androgens of all kinds in 301 
PCOS. However, there was no common pattern, and no study suggested a diagnostic marker or 302 
formula for discriminating PCOS from healthy controls. Nevertheless, for certain androgens (e.g. 303 
total T/DHT (21) or T and androstenedione (22)) a predictive value was reported regarding adverse 304 
metabolic outcome in PCOS. Notably, the most recent studies describe involvement of alternative 305 
routes for androgen excess in PCOS. Saito et al (12) report a role of the alternative backdoor 306 
pathway for androgen overproduction in PCOS. O’Reilly et al (15) found increased 11-oxygenated 307 
androgens in PCOS. We found 14/40 urinary steroid metabolites increased in PCOS, among them 308 
9 androgens and 4 glucocorticoids (Figure 1). Highest increase was found for DHEA, the precursor 309 
androgen for both adrenal and ovarian androgen production indicating a pathomechanism that 310 
targets both organs and/or overall steroidogenesis. Increased androgen metabolites in PCOS were 311 
not only comprised in the classic pathway, but also in the alternative backdoor pathway (e.g. 312 
androsterone, androstanediol), and they were products of 11-oxygenated androgens (e.g. 11β-313 
hydroxy-androsterone). Thus our data confirm a role of the alternative backdoor pathway and of 11-314 
oxygenated androgens in PCOS. As these pathways of androgen production have been neglected 315 
in clinical assessment of PCOS so far, future studies including these metabolites may help in better 316 
describing the androgen profile of PCOS and using it as a diagnostic tool. In accordance with that, 317 
our calculations revealed androstanediol (a metabolite of the backdoor pathway) as the best single 318 
metabolite predictor to discriminate PCOS from controls.  319 
320 
PCOS is defined as not being overlapping with androgen excess due to congenital adrenal 321 
hyperplasias (CAH), mostly 21-hydroxylase deficiency (1, 2). Some studies of ovarian 322 
steroidogenesis suggest that in PCOS activities of HSD3B2 and CYP17-17,20 lyase are enhanced 323 
(24). However, studies looking at steroid enzyme activities assessed by calculating steroid 324 
conversion ratios reveal ambiguous results. Increased 5α reductase activity in PCOS has been 325 
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suggested from clinical studies (13, 23), and was also suggested from immunohistochemical 326 
studies looking at ovarian tissues (11). In our study, we found an increase in 21-hydroxylase, 11β-327 
hydroxylase, 17α-hydroxylase/17,20 lyase (Δ4) as well as 3α-HSD activity in PCOS (Figure 1). By 328 
contrast, we found no clear difference for 3β-HSD activity. Overall, these findings in PCOS do not 329 
fit a pattern for a specific steroid biosynthesis disorder, but they indicate overall enhanced 330 
steroidogenesis and towards androgens specifically. Thus PCOS clearly separates from CAH. 331 
332 
Similar to the urine steroid profiling study by Blumenfeld (23), we found increased androgen and 333 
glucocorticoid metabolites in PCOS. In both studies, 5α reductase activity seemed increased when 334 
looking at its activity within the backdoor pathway (11βOHET/11βOHAT), but not with respect to its 335 
activity in the degradation of mineralocorticoids (THB/5αTHB) and glucocorticoids (THF/5αTHF). 336 
However, this effect seemed associated with BMI in both studies. As 5α reductase activity is 337 
essential to yield androgen precursor metabolites for DHT production, this indicates that in PCOS 338 
an increase in BMI will enhance 5α-dependent androgen production. In line with that, clinical 339 
studies unambiguously show an improvement of hyperandrogenism in PCOS women with weight 340 
loss (2). 341 
Concerning 11β-hydroxysteroid dehydrogenase activities, we found an increased type 2 and 342 
decreased type 1 activity, but no change in absolute cortisol excretion. Blumenfeld suggested a 343 
decrease in type 1 activity from one calculated ratio (23). Diminished HSD11B1 activity has been 344 
previously reported in PCOS (25-28) and may result in a shift of steroidogenesis towards the more 345 
active glucocorticoid products associated with hypercortisolemic adverse effects often manifesting 346 
as the metabolic syndrome. Finally, other studies found an increase in 20α-HSD activity (lower ratio 347 
of THF+αTHF+THE/αC+αCl) (23, 26), while our study revealed diminished 20αHSD and 20β-HSD 348 
activities, but an increase in 3α-HSD activity assessed by the conversion of αTHF and THF to 349 
20αDHF. 20α-HSD activity is mainly promoted by AKR1C1, but may also be promoted by any other 350 
member of the AKR1C superfamily of aldo/keto reductases, which are also known as 3αHSDs. 351 
18 
Generally, 3αHSDs enzymes are expressed tissue specific and are important for the metabolism of 352 
glucocorticoids, progesterones, prostaglandins, and bile acid precursors (5). Concerning 353 
steroidogenesis, 3αHSD activity is highly promoted by AKR1C4 and AKR1C2. In the gonads and 354 
the adrenals 3αHSD catalyzes the conversion of 5α-androstanedione to androsterone and from 355 
17α-OH-dihydro-progesterone to 17α-OH-allopregnanolone in the backdoor pathway (7). Similarly, 356 
it catalyzes the conversion of highly active DHT to almost inactive androstanediol in the prostate. In 357 
previous studies, we have shown that mutations in AKR1C2/4 cause 46,XY undermasculinization 358 
(8), and that in ovarian tissues from PCOS women expression of AKR1C2/4 seemed enhanced 359 
(11). Thus increased 3αHSD activity might be characteristic for hyperandrogenic PCOS similar to 360 
increased 17α-hydroxylase/17,20 lyase activity and 5α reductase activity. Excess activity of all 361 
these enzymes in concert might explain why androstanediol accumulates with PCOS. 362 
363 
Our search for a diagnostic marker from urine steroid profiling using AUC/ROC curve analysis 364 
yielded androstanediol as the best single metabolite for classifying PCOS against controls. This 365 
metabolite is comprised in the backdoor steroid path and may be easily converted to the most 366 
active steroid DHT by oxidative 3αHSD, which is likely promoted by RODH in steroid organs (5). In 367 
fact, RODH expression was found rather increased in PCOS ovarian tissues (11). Taken together a 368 
role of the backdoor pathway for excess androgen production in PCOS seems likely. 369 
To predict PCOS, the best combination including up to four steroids was a ratio comprising 370 
androstanediol, estriol, 20βDHcortisone and cortisol. This ratio was significantly increased in PCOS 371 
compared to controls at a threshold value of ≥435. Taking ratios for steroid analysis bears the 372 
advantage that they are less influenced by different laboratory methods than quantitative steroid 373 
excretion values. Thus, such diagnostic ratios should allow comparison of data between 374 
laboratories as has been shown for normative values of steroid enzyme activities (20). Applying 375 
these diagnostic tools to some preliminary data sets of suspected PCOS women available from our 376 
lab, we found that PCOS diagnosis could be supported in 9/10 subjects using androstanediol as 377 
19 
single classifier and in 6/10 subjects using the best ratio comprising of 4 steroid metabolites. 378 
Importantly, two steroid profiles originating from suboptimal treated patients with 21-hydroxylase 379 
CAH clearly discriminated from both controls and PCOS when looking at the 21-hydroxylase 380 
activity and at the newly developed PCOS activity ratios. In comparison to the classifier 381 
androstanediol, the use of the ratio comprising of 4 steroid metabolites reduces the number of false 382 
positives for PCOS.  383 
384 
Limitations of our study are the relative small sample number and the relatively poor clinical 385 
characterization of the PCOS subjects. However, compared to the study of Blumenfeld (23), in 386 
which only 13 samples were studied, we studied 41 PCOS samples and 66 controls. Clinical 387 
characterization of PCOS subjects is rather difficult as the phenotypical spectrum is broad. Thus 388 
finding a biochemical classifier that discriminates PCOS from non-PCOS is of great clinical interest. 389 
Of course, better metabolic characterization of PCOS samples in future studies may allow to 390 
correlate the steroid data with adverse metabolic outcome, which impacts treatment decisions. 391 
Another disadvantage of our study for practicability is maybe that we performed steroid profiling 392 
from 24h-urine samples and not spot urines or serum. However, it should be feasible to test within 393 
short time, whether the identified PCOS classifiers may also be used on timed spot urines or serum 394 
samples. 395 
396 
In conclusion, our urinary steroid profiling study reveals androstanediol, estriol, 20βDHcortisone, 397 
and cortisol as promising diagnostic markers for PCOS. These so far unsuspected steroids in the 398 
diagnostic workup of PCOS were identified using novel, unbiased approaches for data analysis. 399 
Future studies will aim at confirming their diagnostic use in spot urine and serum specimen as well 400 
as testing their predictive value for adverse metabolic outcome.  401 
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Supporting information captions 500 
501 
S1 Figure. Diagnostic performance of urinary steroid metabolites in the prediction of PCOS. ROC 502 
curves for different classifiers of urinary steroid metabolites are shown on the left side, the corresponding 503 
plots of sensitivity-specificity versus the classifier are shown in the middle, and corresponding contingency 504 
tables on the right side. Dashed lines around the ROC curves indicate the 95% CI of the sensitivity at the 505 
given specificity. The AUC and its 95% CI is indicated. The dashed vertical lines in the sensitivity-specificity 506 
versus classifier plots indicate the threshold where sensitivity and specificity are simultaneously maximized. 507 
The main diagnostic performance parameters corresponding to this threshold are indicated. A-C. Classifier 508 
androstanediol. D-F. The classifier androstanediol/log(androstanediol×estriol) represents the best 509 
combination of 2 steroid metabolites found to achieve the highest possible AUC under the ROC curve. G-I. 510 
The classifier (androstanediol×20β-DH-cortisone)/(20β-DH-cortisone+cortisol) represents the best 511 
combination of 3 steroid metabolites found. J-L. Classifier (androstanediol1.5×20β-DH-cortisone)/(20β-DH-512 
cortisone+ [cortisol×log(estriol)] represents the best combination of 4 steroid metabolites found. 513 
Abbreviations: 5α3αdiol: androstanediol, F: cortisol, 20βDHE: 20β-DH-cortisone, PPV: positive predictive 514 
value, NPV: negative predictive value, log: natural logarithm. 515 
26 
516 
517 
S2 Figure. Association between PCOS, age and body mass index (BMI) with four classifiers derived 518 
from the urine steroid hormone metabolome for the prediction of PCOS. All models were calculated by 519 
linear regression and contain PCOS women and Controls and the covariables age and BMI. Natural logarithm 520 
transformation was applied to all four classifiers as dependent variables on y-axis. The model coefficients are 521 
indicated in Supplemental Table 2. Figures on the left side (A, C, E, G) visualize the association between age 522 
and the log transformed classifier separately for PCOS women and control women adjusted for BMI. Figures 523 
on the right side (B, D, F, H) visualize the association between BMI and the log transformed classifier separately 524 
for PCOS and controls adjusted for age. Figures with the same classifier (dependent variable) derives from the 525 
same model, thus, a total of four multivariable models are described here. Solid black lines indicate regression 526 
lines and the shaped grey area the 95% confidence interval, respectively 527 
27 
528 
S1 Table. Comparison of baseline characteristics. The available number of 
participants (N) for the PCOS and control group and median and 25th-75th quantile are 
indicated. Between-group differences are determined by Mann–Whitney U test (MWU). 
Characteristics 
Controls PCOS MWU 
N Median 25th-75th N Median 25th-75th P 
Age, years  66 34 28-42  41 27 24-32 <0.001 
Weight, kg  66 63 55-70  41 68 58-71 0.26 
Height, cm  66 168 162-171  41 164 158-171 0.071 
Body mass index, kg/m2  66 22.4 19.5-25.7  41 24.0 21-28 0.065 
Systolique blood pressure, mmHg  66 109 102-116  37 115 110-125 0.0019 
Diastolique blood pressure, mmHg  66 71 68-78  37 72 62-80 0.84 
Glucose fasting, plasma, mmol/L  66 4.765 4.4-5.1  17 4.7 4.5-5.3 0.39 
Insulin, mU/L  63 3.2 1-5.8  14 16.6 13.7-22.3 <0.001 
HOMA-IR  63 0.65 0.24-1.12  13 3.74 2.77-4.58 <0.001 
HOMA-β  63 58.2 20.8-113  13 284 106-357 <0.001 
Urine volume 24h, mL  66 1775 1283-2017  41 1670 1250-2200 0.95 
529 
530 
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